Cardiol Therapeutics (CRDL) Share-based Compensation: 2020-2024
Historic Share-based Compensation for Cardiol Therapeutics (CRDL) over the last 5 years, with Dec 2024 value amounting to $10.4 million.
- Cardiol Therapeutics' Share-based Compensation rose 3.52% to $147,287 in Q3 2022 from the same period last year, while for Sep 2022 it was $4.8 million, marking a year-over-year change of. This contributed to the annual value of $10.4 million for FY2024, which is 238.48% up from last year.
- Cardiol Therapeutics' Share-based Compensation amounted to $10.4 million in FY2024, which was up 238.48% from $3.1 million recorded in FY2023.
- In the past 5 years, Cardiol Therapeutics' Share-based Compensation registered a high of $10.4 million during FY2024, and its lowest value of $2.1 million during FY2020.
- Moreover, its 3-year median value for Share-based Compensation was $3.9 million (2022), whereas its average is $5.8 million.
- Per our database at Business Quant, Cardiol Therapeutics' Share-based Compensation crashed by 43.13% in 2022 and then skyrocketed by 238.48% in 2024.
- Yearly analysis of 5 years shows Cardiol Therapeutics' Share-based Compensation stood at $2.1 million in 2020, then spiked by 228.52% to $6.8 million in 2021, then slumped by 43.13% to $3.9 million in 2022, then declined by 20.10% to $3.1 million in 2023, then surged by 238.48% to $10.4 million in 2024.